Kymera Therapeutics annual r&d spending
2019
2020
2021
2022
2023
2024
2025
Kymera Therapeutics R&D Spending Growth & History (KYMR)
Kymera Therapeutics's r&d spending was $316.6M for fiscal 2025.
View full Kymera Therapeutics company overviewKymera Therapeutics annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $316.6M | $76.3M | +31.77% |
| 2024 | 2024-12-31 | $240.2M | $51.2M | +27.06% |
| 2023 | 2023-12-31 | $189.1M | $24.8M | +15.12% |
| 2022 | 2022-12-31 | $164.2M | $27.2M | +19.87% |
| 2021 | 2021-12-31 | $137.0M | $74.9M | +120.62% |
| 2020 | 2020-12-31 | $62.1M | $24.9M | +67.14% |
| 2019 | 2019-12-31 | $37.2M | — | — |
Kymera Therapeutics quarterly r&d spending
Q3.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $119.5M | $41.1M | +52.42% |
| Q1 2026 | 2026-03-31 | $98.2M | $17.9M | +22.31% |
| Q4 2025 | 2025-12-31 | $83.8M | $12.0M | +16.73% |
| Q3 2025 | 2025-09-30 | $74.1M | $13.7M | +22.65% |
| Q2 2025 | 2025-06-30 | $78.4M | $19.2M | +32.41% |
| Q1 2025 | 2025-03-31 | $80.3M | $31.4M | +64.39% |
| Q4 2024 | 2024-12-31 | $71.8M | $18.8M | +35.58% |
| Q3 2024 | 2024-09-30 | $60.4M | $12.3M | +25.55% |
| Q2 2024 | 2024-06-30 | $59.2M | $13.4M | +29.36% |
| Q1 2024 | 2024-03-31 | $48.8M | $6.6M | +15.61% |
| Q4 2023 | 2023-12-31 | $53.0M | $9.8M | +22.80% |
| Q3 2023 | 2023-09-30 | $48.1M | $4.2M | +9.66% |
| Q2 2023 | 2023-06-30 | $45.8M | $4.5M | +10.83% |
| Q1 2023 | 2023-03-31 | $42.2M | $6.3M | +17.48% |
| Q4 2022 | 2022-12-31 | $43.1M | $5.6M | +14.94% |
| Q3 2022 | 2022-09-30 | $43.9M | $5.6M | +14.54% |
| Q2 2022 | 2022-06-30 | $41.3M | $6.1M | +17.24% |
| Q1 2022 | 2022-03-31 | $35.9M | $10.0M | +38.45% |
| Q4 2021 | 2021-12-31 | $37.5M | $17.1M | +84.04% |
| Q3 2021 | 2021-09-30 | $38.3M | $22.5M | +142.78% |
| Q2 2021 | 2021-06-30 | $35.2M | $21.4M | +154.87% |
| Q1 2021 | 2021-03-31 | $26.0M | $13.8M | +114.28% |
| Q4 2020 | 2020-12-31 | $20.4M | — | — |
| Q3 2020 | 2020-09-30 | $15.8M | $4.5M | +39.50% |
| Q2 2020 | 2020-06-30 | $13.8M | — | — |
| Q1 2020 | 2020-03-31 | $12.1M | — | — |
| Q3 2019 | 2019-09-30 | $11.3M | — | — |
Kymera Therapeutics r&d spending trends
Over the last five fiscal years, Kymera Therapeutics's r&d spending increased from $62.1M to $316.6M, a change of $254.5M. The latest reported quarter, Q2 2026, shows $119.5M.
About the metric
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
Calculation and source
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kymera Therapeutics source filings ↗